Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EXPRS2.ST
- Price
- 15.82
- Stock movement down
- -0.14 (-0.88%)
- Company name
- ExpreS2ion Biotech Holding AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 55.85M
- Ent value
- 47.44M
- Price/Sales
- 14.62
- Price/Book
- 1.68
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -21.59%
- 1 year return
- -31.22%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-12
DIVIDENDS
EXPRS2.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 14.62 |
| Price to Book | 1.68 |
| EV to Sales | 12.42 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.53M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -22.87 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 36.88M |
| Net receivables | 16.15M |
| Total current assets | 53.67M |
| Goodwill | 0.00 |
| Intangible assets | 1.65M |
| Property, plant and equipment | 0.00 |
| Total assets | 61.77M |
| Accounts payable | 1.60M |
| Short/Current long term debt | 1.51M |
| Total current liabilities | 27.12M |
| Total liabilities | 28.47M |
| Shareholder's equity | 33.29M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 15.96 |
| Daily high | 16.04 |
| Daily low | 14.96 |
| Daily Volume | 4K |
| All-time high | 2416.00 |
| 1y analyst estimate | 303.00 |
| Beta | 2.64 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Feb 2026 |
Downside potential
Loading...
Downside potential data
| EXPRS2.ST | S&P500 | |
| Current price drop from All-time high | -99.35% | -1.08% |
| Highest price drop | -99.37% | -19.00% |
| Date of highest drop | 1 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -99.06% | -2.64% |
| Avg time to new high | - | 6 days |
| Max time to new high | 296 days | 89 days |
COMPANY DETAILS
Marketcap
55.85M
Marketcap category
Small-cap
Description
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a human clinical Phase III-validated technology platform for the development and production of the active material in vaccines under the GlycoX-S2. Further, it out licenses its ExpreS2 platform to research institutes and pharmaceutical companies; and sells ExpreS2 test kits and reagents for research purposes or diagnostic applications. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.
Employees
20
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found